Skip to main content

Table 3 Safety profile in national registries

From: The safety profile of drotrecogin alfa (activated)

 

UK [17]

Poland [19]

Italy [20]

Canada [21]

Patients (n)

1279

302

324

261

Adverse events (%)

7.4

N/A

N/A

N/A

Bleeding (%)

5.9

6

9

N/A

Serious bleeding (%)

N/A

1.7

4

10

  1. Only the four published national registries in which safety analyses were consistent or part of the objectives of the study are listed here. Note that different definitions were used for bleeding and serious bleeding among registries, and these were also different between registries and controlled clinical trials. N/A = Not available.
Back to article page

Critical Care

ISSN: 1364-8535